From d4a07a6579c32c5ad81428ca02da8fd539efdbc0 Mon Sep 17 00:00:00 2001 From: FMS Date: Wed, 5 Jun 2024 14:14:27 +0200 Subject: [PATCH] Auto saved by Logseq --- pages/STOP2030___Annual Meeting___2024___Session 2.md | 3 ++- 1 file changed, 2 insertions(+), 1 deletion(-) diff --git a/pages/STOP2030___Annual Meeting___2024___Session 2.md b/pages/STOP2030___Annual Meeting___2024___Session 2.md index 33cc7dc9..bc82c7b0 100644 --- a/pages/STOP2030___Annual Meeting___2024___Session 2.md +++ b/pages/STOP2030___Annual Meeting___2024___Session 2.md @@ -9,4 +9,5 @@ - Month 11: strongyloides. we're doing serology for it. - for the CRF: why are we not using directly tablets for it. We're using paper: it was a matter of cost on one site, the CFR is rather short. Maybe its good a idea to put it on paper and transfer it to the CRF. - Stella: In terms of regulatory, if Redcap has trazability entonces sí podemos, pero si no no. Is it possible to sign or countersign. That is one of the things you keep hearing. -- EMA has very strict requirements about software for Clinical trials. \ No newline at end of file +- EMA has very strict requirements about software for Clinical trials. +- We can have source documents that are electronic or not, mainly \ No newline at end of file